Deuterated Melflufen Derivatives for Aqueous Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Melflufen, an anti-tumor agent used in cancer treatment, particularly for multiple myeloma, has stability and handling issues due to its crystalline form, which is difficult to dissolve in aqueous solutions and can form unwanted dimers, leading to potential off-target effects.
Innovation Solution
Development of deuterated melflufen derivatives with a higher abundance of deuterium than naturally occurring levels, which improves stability and handling properties, and when administered, results in increased systemic exposure to the derivative and its active metabolite melphalan.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If crystalline melflufen is used, then high lipophilicity and rapid tissue uptake are achieved, but dissolution in aqueous solutions is difficult and stability is poor
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms in the melflufen molecular structure. This isotopic substitution alters the physical and chemical parameters of the compound, specifically improving its stability in aqueous solutions while maintaining its lipophilic properties and rapid tissue uptake capability. The deuterated form resolves the contradiction by changing the fundamental composition parameters of the molecule.
2Ease of manufacture
If crystalline melflufen is dissolved in highly acidic aqueous solutions, then dissolution is achieved, but the solution is unsuitable for manufacturing and pharmaceutical purposes
Solution Approach 1:
Deuterium substitution changes the molecular parameters of melflufen, enabling it to dissolve in aqueous solutions at pH levels suitable for pharmaceutical manufacturing. The deuterated compound maintains dissolution capability while eliminating the need for highly acidic conditions, thus resolving the contradiction between manufacturability and dissolution requirements.
3Stability of the object's composition
If crystalline melflufen is dissolved in dimethylacetamide and glucose solution, then dissolution is improved, but the preparation is unstable and forms unwanted dimers
Solution Approach 1:
The deuterium substitution alters the chemical reactivity parameters of melflufen, reducing its tendency to form unwanted dimers and improving the stability of the pharmaceutical preparation. The modified molecular structure of deuterated melflufen eliminates the harmful dimerization side reaction while maintaining solubility, resolving the contradiction between preparation stability and harmful byproduct formation.
4Object-affected harmful factors
If organic solvents like DMA are used, then dissolution is improved, but patient safety is compromised and medical devices are damaged
Solution Approach 1:
Deuterium substitution changes the physicochemical parameters of melflufen, enabling it to achieve adequate solubility in safer, more appropriate aqueous or aqueous-based pharmaceutical formulations. This eliminates the need for hazardous organic solvents like DMA, resolving the contradiction between patient safety and solubility requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The deuterated melflufen derivatives achieve higher systemic exposure and prolonged action of melphalan, potentially enhancing therapeutic efficacy while reducing the risk of side effects due to lower required doses.
Implementation Method 1
The present inventors have discovered that deuterated derivatives of melflufen have improved properties compared to melflufen with a natural abundance level of deuterium
Data Source
AI summary
The invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof (Formula I), wherein, each R1-R30 is independently selected from the group consisting of H and deuterium, and at least one of R1-R30 is deuterium with an abundance level greater than the naturally occurring abundance of deuterium. The invention also provides pharmaceutical compositions containing the compounds, and uses of the compounds.